Sign in

CIK 0001806952

  • Non-accelerated filer
  • Smaller reporting company

Lyell Immunopharma, Inc.

Sign in to watch
Ticker
LYEL
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
833006753
Phone
+1 650-695-0677
Business address
201 HASKINS WAY, SOUTH SAN FRANCISCO, CA, 94080
Open-market buys, last 90 days
$49,999,983
in 2 filings
Open-market sales, last 90 days
$215,781
in 9 filings

Net +$49,784,202. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Reading 41 more Form 4s from the SEC; this list fills in as they're read.

Date Insider Transaction Shares Price Value Owned after
2024-02-09 Lee Gary K. Chief Scientific Officer Grant or award +40,000 52,700
2024-02-09 Lee Gary K. Chief Scientific Officer Grant or award · Stock Option (right to buy) +400,000 400,000
2024-02-09 Newton Charles W. Chief Financial Officer Grant or award +40,000 48,729
2024-02-09 Newton Charles W. Chief Financial Officer Grant or award · Stock Option (right to buy) +400,000 400,000
2024-02-09 Seely Lynn President and CEO Grant or award +200,000 200,000
2023-11-16 Newton Charles W. Chief Financial Officer Grant or award · Stock Option (right to buy) +3,612,000 3,612,000
2023-11-16 Newton Charles W. Chief Financial Officer Returned to the company · Stock Option (right to buy) −3,612,000 0
2023-11-16 Newton Charles W. Chief Financial Officer Grant or award · Stock Option (right to buy) +190,000 190,000
2023-11-16 Newton Charles W. Chief Financial Officer Returned to the company · Stock Option (right to buy) −190,000 0
2023-11-16 Newton Charles W. Chief Financial Officer Grant or award · Stock Option (right to buy) +516,000 516,000
2023-11-16 Newton Charles W. Chief Financial Officer Returned to the company · Stock Option (right to buy) −516,000 0
2023-11-16 Newton Charles W. Chief Financial Officer Grant or award · Stock Option (right to buy) +500,000 500,000
2023-11-16 Newton Charles W. Chief Financial Officer Returned to the company · Stock Option (right to buy) −500,000 0
2023-11-16 Lee Gary K. Chief Scientific Officer Grant or award · Stock Option (right to buy) +800,000 800,000
2023-11-16 Lee Gary K. Chief Scientific Officer Returned to the company · Stock Option (right to buy) −800,000 0
2023-11-16 Seely Lynn President and CEO Grant or award · Stock Option (right to buy) +7,500,000 7,500,000
2023-11-16 Seely Lynn President and CEO Returned to the company · Stock Option (right to buy) −7,500,000 0
2023-11-16 Hill Stephen J. Chief Technical Ops. Officer Grant or award · Stock Option (right to buy) +500,000 500,000
2023-11-16 Hill Stephen J. Chief Technical Ops. Officer Returned to the company · Stock Option (right to buy) −500,000 0
2023-11-16 Hill Stephen J. Chief Technical Ops. Officer Grant or award · Stock Option (right to buy) +165,000 165,000

Page 7 of 8 · 156 trades